A Study about Triple Immune Strategy for HIV Remission
Official Title
A Phase I/IIa Randomized, Placebo-Controlled Trial of Conserved-Mosaic T-cell Vaccine in a Regimen with Vesatolimod and Broadly Neutralizing Antibodies in Adults Initiated on Suppressive Antiretroviral Therapy during Acute HIV-1
Purpose
This study will evaluate the safety and efficacy of these treatments in individuals with HIV-1 who started suppressive antiretroviral therapy (ART) during acute HIV-1 infection. The study consists of four steps including an analytical treatment interruption (ATI).
Could this study be right for you?
- Individuals with HIV who started treatment during acute HIV infection
- No known ART interruption >14 consecutive days since ART initiation
- Willingness to participate in analytic treatment interruption
- CD4 count ≥500 within 60 days to study entry
- HIV RNA <50 since initial viral suppression on ART and for at least 1 year prior to study entry